Results 61 to 70 of about 51,607 (296)

Fresh insights into the light‐induced pineal gland circadian rhythm transmission mechanism derived from mRNA and miRNA profiling

Animal Research and One Health, EarlyView.
Mechanisms of light in regulating the chick pineal clock. Abstract The circadian clock significantly impacts animal health and productivity, with light playing a crucial role in regulating circadian rhythms. However, the mechanisms behind light‐induced circadian transmission remain unclear, particularly in light‐sensitive avian species.
Yunlei Li, Yanyan Sun, Jingwei Yuan, Xiangchen Li, Lei Shi, Adamu Mani Isa, Yuanmei Wang, Pingzhuang Ge, Yunhe Zong, Panlin Wang, Jilan Chen   +10 more
wiley   +1 more source

Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia

bioRxiv, 2019
Relapses driven by chemoresistant leukemic cell populations are the main cause of mortality for patients with acute myeloid leukemia (AML). Here, we show that the ectonucleotidase CD39 (ENTPD1) is upregulated in cytarabine (AraC)-resistant leukemic cells
Nesrine Aroua, M. Ghisi, Emeline Boet, Marie-Laure Nicolau-Travers, E. Saland, R. Gwilliam, F. de Toni, M. Hosseini, P. Mouchel, Thomas Farge, Claudie Bosc, Lucille Stuani, Marie Sabatier, Fetta Mazed, C. Larrue, Latifa Jarrou, S. Gandarillas, M. Bardotti, Charlotte Syrykh, C. Laurent, Mathilde Gotanègre, N. Bonnefoy, F. Bellvert, J. Portais, N. Nicot, Francisco Azuale, T. Kaoma, J. Tamburini, F. Vergez, C. Récher, J. Sarry   +30 more
semanticscholar   +1 more source

Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets

Marine Drugs, 2019
The role of the marine environment in the development of anticancer drugs has been widely reviewed, particularly in recent years. However, the innovation in terms of clinical benefits has not been duly emphasized, although there are important ...
Renato B. Pereira, Nikolai M. Evdokimov, Florence Lefranc, Patrícia Valentão, Alexander Kornienko, David M. Pereira, Paula B. Andrade, Nelson G. M. Gomes   +7 more
doaj   +1 more source

Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine

Biomolecules, 2019
Cancer is the second leading cause of death worldwide. The main modality to fight against cancer is surgery, radiotherapy, and chemotherapy, and more recently targeted therapy, gene therapy and immunotherapy, which play important roles in treating cancer
B. Salehi, Z. Selamoğlu, Ksenija S Mileski, R. Pezzani, M. Redaelli, William C. Cho, F. Kobarfard, Sadegh Rajabi, M. Martorell, Pradeep Kumar, N. Martins, Tuhin Subhra Santra, Javad Sharifi‐Rad   +12 more
semanticscholar   +1 more source

Iron overload mediates cytarabine resistance in AML by inhibiting the TP53 signaling pathway

Acta Biochimica et Biophysica Sinica
Currently, chemotherapy remains the primary treatment for acute myeloid leukemia (AML). Drug resistance in AML cells is a critical factor contributing to the failure of chemotherapy remission and subsequent relapse.
Jia Yan, Li Ling, Li Ying, Zhu Xunxun, Wang Haiyan, Xu Bin, Li Qiuping, Zhang Hao   +7 more
doaj   +1 more source

Can pharmacogenetics impact the therapeutic effect of cytarabine and anthracyclines in adult acute myeloid leukaemia patients?: A Serbian experience [PDF]

Journal of Medical Biochemistry
Background: Cytarabine-anthracycline-based induction chemotherapy remains the standard of care for remission induction among patients with newly diagnosed acute myeloid leukaemia (AML).
Pravdić Zlatko, Suvajdžić-Vuković Nada, Virijević Marijana, Mitrović Mirjana, Pantić Nikola, Sabljić Nikica, Pavlović Đorđe, Marjanović Irena, Bukumirić Zoran, Vidović Ana, Jaković Ljubomir, Pavlović Sonja, Gašić Vladimir   +12 more
doaj   +1 more source

A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia

Clinical Cancer Research, 2018
Purpose: CPI-613, a lipoate analogue that inhibits pyruvate dehydrogenase (PDH) and α-ketogluterate dehydrogenase (KGDH), has activity in patients with myeloid malignancies.
T. Pardee, Rebecca G. Anderson, K. Pladna, S. Isom, Lais P. Ghiraldeli, L. Miller, J. Chou, G. Jin, Wei Zhang, L. Ellis, Dmitriy Berenzon, D. Howard, D. Hurd, M. Manuel, S. Dralle, S. Lyerly, B. Powell   +16 more
semanticscholar   +1 more source

Ara C face: Cytarabine related dermatological toxicity

Asian Journal of Medical Sciences, 2022
LTE
Manideepa Maji , Nita Radhakrishnan
doaj   +1 more source

Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine

Cell Death and Disease, 2019
Acute myeloid leukemia (AML) patients display dismal prognosis due to high prevalence of refractory and relapsed disease resulting from chemoresistance. Treatment protocols, primarily based on the anchor drug Cytarabine, remained chiefly unchanged in the
M. Levin, M. Stark, B. Berman, Y. Assaraf   +3 more
semanticscholar   +1 more source

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

International Journal of Cancer, EarlyView.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, Michael W. M. Kühn   +3 more
wiley   +1 more source